semaglutide aha The weight-loss drug Wegovy lowered heart attack risk in a large trial Evaluating the Cardiovascular Benefits of

Its worth a current check

Highlights GLP-1 medicines reduce fat and liver mass more rapidly than skeletal muscle (SKM) Running performance is maintained or improved in mice on GLP-1 medicine GLP-1 medicine modifies the SKM proteome despite similar weight loss as calorie restriction Patients on GLP-1 medicine slightly reduce SKM mass but largely maintain strength Summary The large decrease in body weight with glucagon-like peptide-1 (GLP-1) medicines raises concern about a loss of lean body mass (LBM) and skeletal muscle

Konstantinos Spaniolas, chief of the Division of Bariatric, Foregut and Advanced GI Surgery at Stony Brook Medicine

Semaglutide should not be used during pregnancy